Piramal Enterprises Limited (BSE:500302) will look for acquisitions. The company is looking at multiple acquisition opportunities across its pharma business, including a possible re-entry into domestic formulations, which the company exited in 2010. It is also looking at adding new complex hospital generics through in-licensing, acquisitions, and capital investments, and organic and inorganic addition of consumer healthcare products to leverage the pan-India distribution platform and explore re-entry into domestic formulations. “The Carlyle Group’s recent strategic investment confirms the business’s underlying strength and provides us with a war chest for the next phase of growth,” said Ajay Piramal, Chairman of Piramal Enterprises, in the annual report. “Each of the pharma businesses has a compelling plan for organic growth, with multiple acquisition opportunities. We believe that we will continue to deliver in line with our long-term growth track record through organic initiatives. In addition, we will target a few more acquisitions to further boost our growth,” Piramal said.